We work with leading pharma companies We partner with pharma to discover novel treatments using our Benevolent Platform™. Our expertise spans across the entire drug discovery process, working across any therapeutic area or drug modality. Work with us ...
Allows researchers to: Accelerate development of medicines that drug "undruggable" protein targets. Founded: 2018. Headquarters: San Francisco, California, United States. GT Apeiron TherapeuticsUses AI to: Do something that isn't entirely clear, based on the limited amount of information GT Apeiron ...
Many companies, from biotech start-ups to large pharma, are farming out this aspect of the early drug discovery process—and for good reason. Developing and validating your own internal AI functionalities requires capital and manpower, and it often makes sense to turn to the experts. Our team...
dollars had been invested by 11 out of the world's leading 20 'AI-first' biotech companies in the field of small molecules. 'AI-first' companies are biotech companies for which artificial intelligence/machine learning is the core of their discovery activities. ...
Artificial intelligence (AI)-based drug discovery has not yet completely addressed the numerous and varied challenges posed by the inherent complexities an
AI新药研发策略（AI-based strategies for drug discovery and development）大大加快了这一进程，据英国AI制药公司Exscientia数据，AI将项目立项推进到临床前候选化合物（preclinical candidate compounds）的时间，从平均4年半缩短至约13.7个月，时间缩短近75%。当下，很多传统药企（pharmaceutical companies）正在建立内部AI...
For GenAI-based in-silico drug discovery to achieve widespread adoption, the technology must adhere to several shortcomings. First, in-silico drug discovery requires extensive and updated bioinformatics and cheminformatics datasets. Large datasets are essential to the models’ contextual understanding and ...
AI drug discovery company Syntekabio has partnered with Ukraine-based global compound supplier Enamine for supply, synthesis of compounds and synthetic drug development. Under the Memorandum of Understanding (MOU) signed by the companies, the alliance will leverage an extensive synthetic compound library...
Chemiverse provides a quicker route to ‘the best target, the best chemical,’ according to the Korean biotech Pharos iBio. With its first AI-based drug currently undergoing clinical trials, the company is demonstrating the broad value AI can provide fro
One reason is that drug discovery is difficult: finding and developing an effective medicine is a yearslong and very expensive process. But maybe it doesn’t have to be. Experts say AI—if properly integrated into scientists’ research—could revolutionize drug discovery, making it possible for ...